USFDA successfully concludes inspection at Unichem Labs Ghaziabad facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-02-14 06:45 GMT   |   Update On 2024-03-21 15:22 GMT

Mumbai: Unichem Labs has announced that the United States Food and Drug Administration (USFDA) has successfully concluded inspection without any observation at the Company's Ghaziabad (Uttar Pradesh) formulation facility.The inspection was held from February 7, 2024 to February 13, 2024."The United States Food and Drug Administration (USFDA) conducted inspection at the Company’s...

Login or Register to read the full article

Mumbai: Unichem Labs has announced that the United States Food and Drug Administration (USFDA) has successfully concluded inspection without any observation at the Company's Ghaziabad (Uttar Pradesh) formulation facility.

The inspection was held from February 7, 2024 to February 13, 2024.

"The United States Food and Drug Administration (USFDA) conducted inspection at the Company’s Ghaziabad (Uttar Pradesh) formulation facility from February 7, 2024 to February 13, 2024. The inspection was successfully concluded without any observation," Unichem Labs stated in a BSE filing.
"The Company takes the quality and compliance issues with utmost importance and remains committed to maintain the same across all its manufacturing facilities," it further added.

Headquartered in Mumbai, Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. The company was founded in 1944 by Padmabhushan Late Mr. Amrut V Mody. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

Read also: USFDA nod to Unichem Labs Prasugrel Tablets to reduce thrombotic CV events rate in acute coronary syndrome





Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News